| Gene symbol | APOB | Synonyms | FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48 | Type of gene | protein-coding | |
| Chromosome | 2 | Map location | 2p24.1 | dbXrefs | Entrez:338 MIM:107730 HGNC:HGNC:603 Ensembl:ENSG00000084674 AllianceGenome:HGNC:603 | |
| Gene perturbation-related omics dataset | PertOrg | |||||
| Description | apolipoprotein B | |||||
| GTO ID | GTC1349 |
| Trial ID | NCT01090661 |
| Disease | Familial Hypercholesterolemia |
| Altered gene | APOB |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | ISIS 301012|mipomersen sodium|Kynamro |
| Co-treatment | placebo |
| Location approved | US, Mexico, Argentina, South Korea |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Randomized Double-Blinded Crossover Trial to Define the ECG Effects of Mipomersen (ISIS 301012) Using a Therapeutic and Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial |
| Year | 2010 |
| Country | United States |
| Company sponsor | Kastle Therapeutics, LLC |
| Other ID(s) | MIPO2800209 |
| Vector information | |||
|
|||
| Cohort1: mipomersen_Placebo | |||||||
|
|||||||
| Cohort2: moxifloxacin | |||||||
|
|||||||
| Cohort3: Placebo | |||||||
|
|||||||